FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138343003> ?p ?o ?g. }

• W2138343003 endingPage "165" @default.
• W2138343003 startingPage "155" @default.
• W2138343003 abstract "Recombinant human erythropoietin (rHuEpo) was introduced into clinical practice more than a decade ago, and has been found to be effective in the treatment of several types of anemia, including anemia of end-stage renal failure and cancer-related anemia. No study has suggested that Epo might have an effect on the biology of the disease, nor any survival advantage to cancer patients treated with Epo for anemia has been reported. Here we report six patients with advanced multiple myeloma (MM) with very poor prognostic features, whose expected survival was <6 months. All six patients were treated with rHuEpo for their anemia, either without any chemotherapy or very mild chemotherapy for a short time. Yet, surprisingly they lived for 45-133 months totally from MM diagnosis and 38-94 months with rHuEpo (with a good quality of life). In fact, one patient, is still alive and well, more than 8 yr after chemotherapy was discontinued because of a resistant aggressive disease. The course in these six MM patients led us to hypothesize that Epo might have an antineoplastic or antimyeloma effect. We proceeded and tested that hypothesis in mouse models of myeloma (Mittelman M et al., Proc Natl Acad Sci USA 98:5181,2001). In these models we confirmed that rHuEpo induced tumor regression in about 50% of the BALB/c mice inoculated with MOPC-315 myeloma cells. We then presented evidence that the mechanism is a new immune-mediated phenomenon, via activation of CD8+ T cells. Furthermore, evidence from the literature supports the antineoplastic effect of Epo. Epo might be used as an adjunct immune treatment in various malignant diseases, in addition to the current regimens and chemotherapeutic protocols. Future trials should determine the role of Epo in myeloma and cancer treatment, besides clarifying concerns about the presence of Epo receptors on some tumor cells." @default.
• W2138343003 created "2016-06-24" @default.
• W2138343003 creator A5001731035 @default.
• W2138343003 creator A5003327673 @default.
• W2138343003 creator A5029981922 @default.
• W2138343003 creator A5048794053 @default.
• W2138343003 creator A5056694098 @default.
• W2138343003 creator A5068763564 @default.
• W2138343003 creator A5084531288 @default.
• W2138343003 date "2004-02-03" @default.
• W2138343003 modified "2023-10-15" @default.
• W2138343003 title "Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies" @default.
• W2138343003 cites W146679683 @default.
• W2138343003 cites W1484334243 @default.
• W2138343003 cites W1504583940 @default.
• W2138343003 cites W1531229638 @default.
• W2138343003 cites W1821554592 @default.
• W2138343003 cites W1867073577 @default.
• W2138343003 cites W1884165293 @default.
• W2138343003 cites W1885881044 @default.
• W2138343003 cites W1894906437 @default.
• W2138343003 cites W1967978314 @default.
• W2138343003 cites W1970360147 @default.
• W2138343003 cites W1974694639 @default.
• W2138343003 cites W1990059053 @default.
• W2138343003 cites W1993484356 @default.
• W2138343003 cites W2005460762 @default.
• W2138343003 cites W2006382315 @default.
• W2138343003 cites W2013108383 @default.
• W2138343003 cites W2014481700 @default.
• W2138343003 cites W2016833484 @default.
• W2138343003 cites W2017606827 @default.
• W2138343003 cites W2019289959 @default.
• W2138343003 cites W2026112841 @default.
• W2138343003 cites W2034612444 @default.
• W2138343003 cites W2038106939 @default.
• W2138343003 cites W2040533210 @default.
• W2138343003 cites W2044769464 @default.
• W2138343003 cites W2053166134 @default.
• W2138343003 cites W2088782995 @default.
• W2138343003 cites W2091061603 @default.
• W2138343003 cites W2097294766 @default.
• W2138343003 cites W2102546064 @default.
• W2138343003 cites W2110612111 @default.
• W2138343003 cites W2112652415 @default.
• W2138343003 cites W2129939791 @default.
• W2138343003 cites W2140830841 @default.
• W2138343003 cites W2142463112 @default.
• W2138343003 cites W2153903059 @default.
• W2138343003 cites W2285891107 @default.
• W2138343003 cites W2329804409 @default.
• W2138343003 cites W233692421 @default.
• W2138343003 cites W2340124568 @default.
• W2138343003 cites W2411671994 @default.
• W2138343003 cites W2418264522 @default.
• W2138343003 cites W2418765237 @default.
• W2138343003 cites W269470825 @default.
• W2138343003 cites W3025393355 @default.
• W2138343003 cites W4231292559 @default.
• W2138343003 cites W4243040283 @default.
• W2138343003 cites W4246301691 @default.
• W2138343003 cites W4294233646 @default.
• W2138343003 doi "https://doi.org/10.1046/j.0902-4441.2003.00190.x" @default.
• W2138343003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14962233" @default.
• W2138343003 hasPublicationYear "2004" @default.
• W2138343003 type Work @default.
• W2138343003 sameAs 2138343003 @default.
• W2138343003 citedByCount "45" @default.
• W2138343003 countsByYear W21383430032012 @default.
• W2138343003 countsByYear W21383430032013 @default.
• W2138343003 countsByYear W21383430032014 @default.
• W2138343003 countsByYear W21383430032016 @default.
• W2138343003 countsByYear W21383430032017 @default.
• W2138343003 crossrefType "journal-article" @default.
• W2138343003 hasAuthorship W2138343003A5001731035 @default.
• W2138343003 hasAuthorship W2138343003A5003327673 @default.
• W2138343003 hasAuthorship W2138343003A5029981922 @default.
• W2138343003 hasAuthorship W2138343003A5048794053 @default.
• W2138343003 hasAuthorship W2138343003A5056694098 @default.
• W2138343003 hasAuthorship W2138343003A5068763564 @default.
• W2138343003 hasAuthorship W2138343003A5084531288 @default.
• W2138343003 hasConcept C121608353 @default.
• W2138343003 hasConcept C126322002 @default.
• W2138343003 hasConcept C143998085 @default.
• W2138343003 hasConcept C203014093 @default.
• W2138343003 hasConcept C2776364478 @default.
• W2138343003 hasConcept C2776694085 @default.
• W2138343003 hasConcept C2778248108 @default.
• W2138343003 hasConcept C2778534260 @default.
• W2138343003 hasConcept C2779134260 @default.
• W2138343003 hasConcept C71924100 @default.
• W2138343003 hasConcept C8891405 @default.
• W2138343003 hasConceptScore W2138343003C121608353 @default.
• W2138343003 hasConceptScore W2138343003C126322002 @default.
• W2138343003 hasConceptScore W2138343003C143998085 @default.
• W2138343003 hasConceptScore W2138343003C203014093 @default.
• W2138343003 hasConceptScore W2138343003C2776364478 @default.
• W2138343003 hasConceptScore W2138343003C2776694085 @default.

• next